SlideShare a Scribd company logo
1 of 62
Download to read offline
OPIOID ANALGESICS
Dr. Kiran A. Kantanavar
• A boy aged 14 years is brought to the hospital
emergency with crush injury of both lower legs.
• An eye witness who brought the boy told that a
bus had run over his legs about 20 min. ago.
• The legs were crushed but he had not bled much.
He also told that initially the boy was shrieking in
pain, but had fainted on way to the hospital.
• Preliminary examination reveals that the patient is
in a semiconscious state, looks pale, the pulse is
fast, low volume and collapsing.
• Both legs have sustained multiple fractures, the
skin and soft tissues have lacerated from which
blood is oozing, but there is no active bleeding.
• There is no apparent head injury.
• Should any medicine be administered
immediately, before even completing a thorough
physical examination?
• If so, which drug, by what route, and why?
PAIN
Opioid analgesics
Opioid analgesics
Opium
• Papaver somniferum and P. album
Papaver somniferum
Opium
• Papaver somniferum and P. album
• Rigveda – “soma”
• Eber’s papyrus (1500 BC)
• Friedrich serturner
• Greek god of dreams – “Morpheus”
Opioid analgesics
Alkaloids of opium
• Opiates vs Opioids
OPIOID RECEPTORS
• μ, δ, and κ (MOR, DOR, and KOR)
• Rhodopsin family of GPCRs (GRAFS classification)
• Transducer mechanisms: Gi/Go proteins
Opioid analgesics
OPIOID RECEPTORS
• μ, δ, and κ (MOR, DOR, and KOR)
• Rhodopsin family of GPCRs
• Transducer mechanisms: Gi/Go proteins
• μ and κ: reduce intracellular cAMP formation
and open K+ channels (mainly)
• δ: suppresses voltage gated N type Ca2+
channels (mainly)
• Neuronal hyperpolarization and reduced
availability of intracellular Ca2+ → decreased
neurotransmitter release
Common:
•Analgesia
•Resp. depression
•Reduced GI motility
Opioid analgesics
Opioid analgesics
Consequences of opioid receptor
activation
1. Internalization
2. Desensitization
3. Tolerance
4. Dependence
5. Addiction
Internalization
• μ and δ receptors: endocytic, β-arrestin-
mediated
• κ receptors: do not internalize
Desensitization
• Acute tolerance or desensitization
• Receptor specific
• Phosphorylation of the receptors resulting in
an uncoupling of the receptor from its G-
protein and/or internalization
Tolerance
• Decrease in the apparent effectiveness of a drug
• With continuous or repeated agonist
administration (days to weeks)
• Following removal of the agonist, disappears
over several weeks
• Right shift in the dose-effect curve
• Cross-tolerance is not consistent or complete
Tolerance
Mild:
• Miosis
Moderate:
• Constipation
• Emesis
• Analgesia
• Sedation
Rapid:
• Euphorigenic
Dependence
“a state of adaptation manifested by
receptor/drug class-specific withdrawal
syndrome produced by cessation of drug
exposure (e.g., by drug abstinence) or
administration of an antagonist”
Dependence
Withdrawal is manifested by
• Agitation
• Hyperalgesia
• Hyperthermia
• Hypertension
• Diarrhea
• Pupillary dilation
• Release of virtually all pituitary
and adrenomedullary hormones
Affective symptoms
• Dysphoria
• Anxiety
• Depression
somatomotor and
autonomic outflow
Addiction
“a behavioral pattern characterized by
compulsive use of a drug”
• Driving force: rewarding effects of opiates
• Avoidance and alleviation of withdrawal
symptoms
MECHANISMS OF
TOLERANCE/DEPENDENCE-
WITHDRAWAL
• Receptor Disposition
• Adaptation of Intracellular Signaling
Mechanisms in the Opioid Receptor-Bearing
Neurons
• System Level Counter-Adaptation
Classification
Natural opium
alkaloids:
1.Morphine,
2.Codeine
Semisynthetic opiates:
1.Diacetylmorphine (Heroin),
2.Pholcodeine,
3.Ethylmorphine
Synthetic opioids:
1.Pethidine (Meperidine),
2.Fentanyl,
3.Methadone,
4.Dextropropoxyphene,
5.Tramadol.
Morphine – Pharmacological actions
CNS
 Depressant
• Analgesia
• Sedation
• Mood
• Respiratory centre
• Cough centre
• Temperature centre
• Vasomotor centre
• Thalamus -
hypothalamus
 Stimulant
• CTZ
• Edinger Westpal nucleus
• Vagal centre
• Cortical & hippocampal cells
CVS
• Vasodilatation
• Hypotension
• Bradycardia
GIT
• Constipation
 Others
• Bronchi: histamine -> bronchoconstriction
• Biliary tract: spasm
• Urinary bladder: detrussor vs sphincter
• Uterus: no significant effect
• Hyperglycemia
• Pruritus
Analgesia
• Dose related
• Peripheral vs neuritic
• Visceral vs somatic
• Dull poorly localised vs sharp shooting
localised
• Pain associated components
• Spinal & supraspinal
• Peripheral action of opioid
Sites of action of
Morphine.
A: Direct action of
opioids on inflamed
or damaged
peripheral tissues.
B: Inhibition also
occurs in the spinal
cord.
C: Possible sites of
action in the
thalamus.
The pain-inhibitory
neuron is indirectly
activated by opioids,
which inhibits an
inhibitory (GABAergic)
interneuron.
Opioid
analgesic
action on the
descending
inhibitory
pathway
Clinical uses
 Analgesia
• Traumatic
• Visceral
• Ischemic
• Burn
• Post operative
• Cancer
• Renal colic
 Acute pulmonary edema
& CCF
 Cough
 Diarrhea
 Shivering
 Anaesthesia
• Surgical anaesthesia
• Pre anaesthetic
medication
Adverse effects
• Acute morphine poisoning
– Toxicity: 50mg; Lethal: 250mg
– Antidote: Naloxone 0.4 to 0.8mg i.v.
• Resp. depression & apnea in newborn
• CVS: Hypotension & Bradycardia
• Allergy & Pruritus
• Tolerance & Dependence
CASE STUDY
A 60-year-old man with a history of moderate chronic
obstructive pulmonary disease presents in the
emergency department with a broken hip suffered in
an automobile accident. He complains of severe pain.
• What is the most appropriate immediate treatment
for his pain?
• Are any special precautions needed?
TO BE CONTINUED..
Codeine
• Methyl-morphine
• Partial agonist at μ opioid receptor with a low
ceiling effect
• More selective cough suppressant
• Degree of analgesia is comparable to aspirin
• Demethylation by CYP2D6  morphine
• Constipation is a prominent side effect  Rx of
diarrhea
• Abuse liability is low
Heroin
• Diacetylmorphine  6-monoacetylmorphine 
morphine
• Euphorient especially on i.v. injection and highly
addicting
• Sedative, emetic and hypotensive actions are less
prominent
• Banned in most countries except U.K
LEVORPHANOL
• Opioid agonist of the morphinan series
• Pharmacological effects parallel those of
morphine
• Less nausea and vomiting
• Metabolized less rapidly than morphine  long
acting (t1/2 of 12-16 hr)
• D-isomer (dextrorphan)
– Devoid of analgesic action
– Has inhibitory effects at NMDA receptors
Pethidine (Meperidine)
• Synthesized as an atropine substitute in 1939
• μ opioid receptor agonist and its actions are blocked
by naloxone
• Special features:
1. Analgesic potency
2. Onset of action
3. Cough
4. Spasmodic action on
smooth muscles
5. Sedation and euphoria
6. Tachycardia
7. Histamine release
8. Local anaesthesia
9. Norpethidine & Serotonin
syndrome
10. Preferred opioid
analgesic during labour
DIPHENOXYLATE
• Meperidine congener
• Definite constipating effect in humans
• Even its salts are virtually insoluble in aqueous
solution  less abuse potential
• Diphenoxylate hydrochloride is available only
in combination with atropine sulfate
• Difenoxin, a metabolite of diphenoxylate,
– marketed in a fixed dose with atropine
LOPERAMIDE
• A piperidine derivative
• Antidiarrheal effect:
o slows GI motility by effects on the circular and
longitudinal muscles of the intestine
o reduces of GI secretion
• Does not penetrate well into the brain due to the
exporting activity of P-glycoprotein
FENTANYL
• Synthetic opioid related to the phenylpiperidines
• 80–100 times more potent than morphine
• Very important drugs in anesthetic practice
because
1. Relatively short time to peak analgesic effect
2. Rapid termination of effect after small
bolus doses
3. Cardiovascular safety
4. Capacity to significantly reduce the dosing
requirement for the volatile agents
METHADONE
• Long-acting MOR agonist
• Pharmacological properties qualitatively similar to those
of morphine
• L-methadone -> 8-50 times more potent than D-isomer
& has analgesic activity
• D-methadone -> possesses antitussive activity
-> Lacks respiratory depressant action and addiction
liability
• Cumulates in tissues on repeated administration —
duration of action is progressively lengthened
• Abuse potential is rated lower than morphine
• Used primarily as substitution therapy for opioid
dependence
PROPOXYPHENE
• Long-acting MOR agonist, strucurally related to
methadone
• Pharmacological properties qualitatively similar to those
of morphine
• D-propoxyphene -> 8-50 times more potent than L-
isomer & has analgesic activity
• L-propoxyphene -> possesses antitussive activity
• Marketed only in combination with paracetamol ± other
drugs
TRAMADOL
• Synthetic codeine analog that is a weak μ agonist
• Inhibits reuptake of NA and 5-HT
Increases 5-HT release
Thus activates monoaminergic spinal inhibition
of pain
• less respiratory depression, sedation,
constipation, urinary retention and rise in
intrabiliary pressure
• ‘serotonin syndrome’
TAPENTADOL.
• Structurally & mechanistically similar to tramadol
• Displays a mild opioid activity
• Possesses monoamine reuptake inhibitor activity
• Considered similar to tramadol in activity,
efficacy and side-effect profile
• NUCYNTA
• COMPLEX ACTION OPIOIDS AND
OPIOID ANTAGONISTS
1. Agonist-antagonists (κ analgesics)
Nalorphine, Pentazocine, Butorphanol
2. Partial/weak µ agonist + κ antagonist
Buprenorphine
3. Pure antagonists
Naloxone, Naltrexone, Nalmefene
Nalorphine (Nalbuphine)
• N-allyl-normorphine
• first opioid antagonist introduced in 1951
• KOR agonist-MOR antagonist
• not used clinically because of dysphoric and
psychotomimetic effects.
Pentazocine
• Synthesized as part of a deliberate effort to
develop an effective analgesic with little or no
abuse potential
• Weak μ antagonist and strong κ agonist
• Analgesia - spinal (κ1)
• Lower ceiling Sedation and respiratory depression
• Tachycardia and rise in BP-sympathetic stimulation
• Biliary spasm and constipation – less prominent
• Low dose – pleasurable; high dose- unpleasurable
(σ mediated)
Recognised by post-addicts as an opiate
Tolerance, psychological and physical
dependence
‘Drug seeking’
Withdrawal syndrome has features of both
morphine and nalorphine abstinence
 Uses: Postoperative and moderately severe pain
in burns, trauma, fracture & cancer
 Combination of pentazocine with naloxone
reduces the potential misuse of tablets
Butorphanol
• KOR agonist and MOR antagonist
• Actions similar to pentazocine
• Dysphoric & Psychotomimetic effects are not
prominent (weaker σ agonist)
• Recognised by post-addicts as an barbiturate
Tolerance, physical dependence and withdrawal
(mild)
• Can neither substitute for, nor antagonize
morphine (weak interaction with µ receptors)
• postoperative and other short-lasting (e.g. renal
colic) painful conditions
Buprenorphine
• It substitutes for morphine at low levels of
morphine dependence
• Precipitates withdrawal in highly morphine
dependent subjects
• Long-lasting painful conditions requiring an
opioid analgesic (cancer pain)
• Premedication, postoperative pain, in myocardial
infarction and in the treatment of morphine
dependence.
• Naloxone (high dose) can prevent buprenorphine
effect but does not reverse it - not used during
labour
Naloxone
• It is N-alylnor-oxymorphone
• Competitive antagonist on all types of opioid
receptors
• No
– Agonistic action
– Autonomic action
– Physical/psychological dependence
• Antagonizes all actions of morphine
• Antagonizes the agonistic actions of nalorphine,
pentazocine @higher doses
• Naloxone also blocks the actions of endogenous
opioid peptides
– blocks placebo, acupuncture and stress-induced
analgesia
• Naloxone partly antagonizes respiratory
depression produced by certain nonopioids,
e.g. N2O, diazepam
• Uses:
– drug of choice for morphine poisoning (0.4–0.8 mg
i.v. every 2– 3 min: max 10 mg)
– reversing neonatal asphyxia due to opioid use during
labour
– overdose with other opioids and agonistantagonists
(except buprenorphine)
– diagnosis of opioid dependence
Naltrexone
• chemically related to naloxone
• more potent than naloxone
• orally active and having a long duration
of action
• ‘opioid blockade’ therapy of post addicts
• Alcohol craving is also reduced by naltrexone
– approved for prevention of relapse of heavy drinking
Methyl naltrexone
• derivative of naltrexone
• does not penetrate the blood-brain barrier
• effectively blocks peripheral action of μ opioids
• used to reverse constipation in
– cancer patients receiving chronic opioid
analgesia
– those taking methadone maintenance
therapy.
References :-
• Goodman & Gilman’s The Pharmacological Basis of
Therapeutics; 12th edition.
• Basic & Clinical Pharmacology – Katzung ; 13th edition.
• Essentials of Medical Pharmacology - KD Tripathi; 6th edition.

More Related Content

What's hot

Opioid analgesics
Opioid analgesicsOpioid analgesics
Opioid analgesicsRyma Chohan
 
Opioid receptors & opioid analgesics
Opioid receptors & opioid analgesicsOpioid receptors & opioid analgesics
Opioid receptors & opioid analgesicsHeena Parveen
 
Opioid Agonists And Antagonists
Opioid Agonists And AntagonistsOpioid Agonists And Antagonists
Opioid Agonists And AntagonistsDr Shah Murad
 
Opioid analgesics
Opioid analgesicsOpioid analgesics
Opioid analgesicsfarhan_aq91
 
Anticholinergics and drugs acting on autonomic ganglia- drdhriti
Anticholinergics and drugs acting on autonomic ganglia- drdhritiAnticholinergics and drugs acting on autonomic ganglia- drdhriti
Anticholinergics and drugs acting on autonomic ganglia- drdhritihttp://neigrihms.gov.in/
 
Ganglionic stimulants and blockers suffi
Ganglionic stimulants and blockers suffiGanglionic stimulants and blockers suffi
Ganglionic stimulants and blockers suffiDr.UMER SUFYAN M
 
Skeletal muscle relaxants, Neuromuscular blocking agents, Neuromuscular blockers
Skeletal muscle relaxants, Neuromuscular blocking agents, Neuromuscular blockersSkeletal muscle relaxants, Neuromuscular blocking agents, Neuromuscular blockers
Skeletal muscle relaxants, Neuromuscular blocking agents, Neuromuscular blockersPranav Bansal
 
Serotonin and anti serotonin drugs
Serotonin and anti serotonin drugsSerotonin and anti serotonin drugs
Serotonin and anti serotonin drugsNaser Tadvi
 
Opioids
Opioids		Opioids
Opioids Khalid
 

What's hot (20)

Opioid analgesics
Opioid analgesicsOpioid analgesics
Opioid analgesics
 
Opioid analgesic
Opioid analgesicOpioid analgesic
Opioid analgesic
 
Opioid receptors & opioid analgesics
Opioid receptors & opioid analgesicsOpioid receptors & opioid analgesics
Opioid receptors & opioid analgesics
 
Skeletal muscle relaxant
Skeletal muscle relaxantSkeletal muscle relaxant
Skeletal muscle relaxant
 
Antiparkinsonian drugs - drdhriti
Antiparkinsonian drugs - drdhriti Antiparkinsonian drugs - drdhriti
Antiparkinsonian drugs - drdhriti
 
Opioid Agonists And Antagonists
Opioid Agonists And AntagonistsOpioid Agonists And Antagonists
Opioid Agonists And Antagonists
 
Opioid analgesics
Opioid analgesicsOpioid analgesics
Opioid analgesics
 
pharmacology of opioids analgesics
pharmacology of opioids analgesicspharmacology of opioids analgesics
pharmacology of opioids analgesics
 
Anticholinergic drugs
Anticholinergic drugsAnticholinergic drugs
Anticholinergic drugs
 
Anticholinergics and drugs acting on autonomic ganglia- drdhriti
Anticholinergics and drugs acting on autonomic ganglia- drdhritiAnticholinergics and drugs acting on autonomic ganglia- drdhriti
Anticholinergics and drugs acting on autonomic ganglia- drdhriti
 
Antiepileptics
AntiepilepticsAntiepileptics
Antiepileptics
 
ANTICHOLINESTERASE DRUGS
ANTICHOLINESTERASE DRUGSANTICHOLINESTERASE DRUGS
ANTICHOLINESTERASE DRUGS
 
Ganglionic stimulants and blockers suffi
Ganglionic stimulants and blockers suffiGanglionic stimulants and blockers suffi
Ganglionic stimulants and blockers suffi
 
General Anesthetics
General AnestheticsGeneral Anesthetics
General Anesthetics
 
Skeletal muscle relaxants, Neuromuscular blocking agents, Neuromuscular blockers
Skeletal muscle relaxants, Neuromuscular blocking agents, Neuromuscular blockersSkeletal muscle relaxants, Neuromuscular blocking agents, Neuromuscular blockers
Skeletal muscle relaxants, Neuromuscular blocking agents, Neuromuscular blockers
 
Serotonin and anti serotonin drugs
Serotonin and anti serotonin drugsSerotonin and anti serotonin drugs
Serotonin and anti serotonin drugs
 
General anaesthetics
General anaesthetics General anaesthetics
General anaesthetics
 
Analgesics
AnalgesicsAnalgesics
Analgesics
 
Opioids
OpioidsOpioids
Opioids
 
Opioids
Opioids		Opioids
Opioids
 

Viewers also liked

Headache management
Headache management Headache management
Headache management PS Deb
 
PPt on Opioid Analgesics for paramedical students (BPT/BSc Nursing)
PPt on Opioid Analgesics for paramedical students (BPT/BSc Nursing)PPt on Opioid Analgesics for paramedical students (BPT/BSc Nursing)
PPt on Opioid Analgesics for paramedical students (BPT/BSc Nursing)Dhruva Sharma
 
Management of pregnant patients in oral surgery
Management of pregnant patients in oral surgeryManagement of pregnant patients in oral surgery
Management of pregnant patients in oral surgeryManjari Reshikesh
 
Painless labour
Painless labourPainless labour
Painless labourdrmcbansal
 
Accrediate-CSR-With Tools Details
Accrediate-CSR-With Tools DetailsAccrediate-CSR-With Tools Details
Accrediate-CSR-With Tools DetailsAtul Joshi
 
SWISSWAY GOLD 1500
SWISSWAY GOLD 1500SWISSWAY GOLD 1500
SWISSWAY GOLD 1500Yesh Lazarte
 
An eoq model with stock dependent demand
An eoq model with stock dependent demandAn eoq model with stock dependent demand
An eoq model with stock dependent demandDivyesh Solanki
 
Nahha Course Catalog (2)
Nahha Course Catalog (2)Nahha Course Catalog (2)
Nahha Course Catalog (2)iHawaiidigital
 

Viewers also liked (14)

Headache management
Headache management Headache management
Headache management
 
PPt on Opioid Analgesics for paramedical students (BPT/BSc Nursing)
PPt on Opioid Analgesics for paramedical students (BPT/BSc Nursing)PPt on Opioid Analgesics for paramedical students (BPT/BSc Nursing)
PPt on Opioid Analgesics for paramedical students (BPT/BSc Nursing)
 
Management of pregnant patients in oral surgery
Management of pregnant patients in oral surgeryManagement of pregnant patients in oral surgery
Management of pregnant patients in oral surgery
 
Painless labour
Painless labourPainless labour
Painless labour
 
Animals
AnimalsAnimals
Animals
 
Accrediate-CSR-With Tools Details
Accrediate-CSR-With Tools DetailsAccrediate-CSR-With Tools Details
Accrediate-CSR-With Tools Details
 
6. anexo-normas-apa-1
6.  anexo-normas-apa-16.  anexo-normas-apa-1
6. anexo-normas-apa-1
 
Dopod 5s
Dopod 5sDopod 5s
Dopod 5s
 
CAPSTONE FINAL PROJECT
CAPSTONE FINAL PROJECTCAPSTONE FINAL PROJECT
CAPSTONE FINAL PROJECT
 
SWISSWAY GOLD 1500
SWISSWAY GOLD 1500SWISSWAY GOLD 1500
SWISSWAY GOLD 1500
 
An eoq model with stock dependent demand
An eoq model with stock dependent demandAn eoq model with stock dependent demand
An eoq model with stock dependent demand
 
Gideon
GideonGideon
Gideon
 
SWISSWAY 1500
SWISSWAY 1500SWISSWAY 1500
SWISSWAY 1500
 
Nahha Course Catalog (2)
Nahha Course Catalog (2)Nahha Course Catalog (2)
Nahha Course Catalog (2)
 

Similar to Opioid analgesics

Similar to Opioid analgesics (20)

Opioid analgesics
Opioid analgesics Opioid analgesics
Opioid analgesics
 
Opioids.pptx
Opioids.pptxOpioids.pptx
Opioids.pptx
 
dr. Ike - update on opioid pharmacology
dr. Ike - update on opioid pharmacologydr. Ike - update on opioid pharmacology
dr. Ike - update on opioid pharmacology
 
Opioid pharmacology
Opioid pharmacologyOpioid pharmacology
Opioid pharmacology
 
narcotic chnaged 1.pptx
narcotic chnaged 1.pptxnarcotic chnaged 1.pptx
narcotic chnaged 1.pptx
 
Recent advances in pain management
Recent advances in pain managementRecent advances in pain management
Recent advances in pain management
 
Pharmacology of pain
Pharmacology of painPharmacology of pain
Pharmacology of pain
 
opioid anlagesic and its antagonist
opioid anlagesic and its antagonistopioid anlagesic and its antagonist
opioid anlagesic and its antagonist
 
Opioids
Opioids Opioids
Opioids
 
Drug used in Mechanical Ventilation
Drug used in Mechanical VentilationDrug used in Mechanical Ventilation
Drug used in Mechanical Ventilation
 
Sedation and analgesia
Sedation and analgesiaSedation and analgesia
Sedation and analgesia
 
Opioids analgeics, Opiod dependence
Opioids analgeics, Opiod dependenceOpioids analgeics, Opiod dependence
Opioids analgeics, Opiod dependence
 
nsaids and opiods in pmr
nsaids and opiods in pmrnsaids and opiods in pmr
nsaids and opiods in pmr
 
Opiods pharmacology revision notes
Opiods pharmacology revision notesOpiods pharmacology revision notes
Opiods pharmacology revision notes
 
OPOIDS by Dr. Nadeem Korai
OPOIDS by Dr. Nadeem KoraiOPOIDS by Dr. Nadeem Korai
OPOIDS by Dr. Nadeem Korai
 
Pain control in surgical patients
Pain control in surgical patientsPain control in surgical patients
Pain control in surgical patients
 
7. PHARMACOLOGY II-1.pdf
7. PHARMACOLOGY II-1.pdf7. PHARMACOLOGY II-1.pdf
7. PHARMACOLOGY II-1.pdf
 
HYPNOTIC & SEDATIVES for class.pptx
HYPNOTIC & SEDATIVES for class.pptxHYPNOTIC & SEDATIVES for class.pptx
HYPNOTIC & SEDATIVES for class.pptx
 
Antiparkinsons drugs
Antiparkinsons drugsAntiparkinsons drugs
Antiparkinsons drugs
 
pre-medication.pptx
pre-medication.pptxpre-medication.pptx
pre-medication.pptx
 

Recently uploaded

ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 

Recently uploaded (20)

ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 

Opioid analgesics

  • 2. • A boy aged 14 years is brought to the hospital emergency with crush injury of both lower legs. • An eye witness who brought the boy told that a bus had run over his legs about 20 min. ago. • The legs were crushed but he had not bled much. He also told that initially the boy was shrieking in pain, but had fainted on way to the hospital. • Preliminary examination reveals that the patient is in a semiconscious state, looks pale, the pulse is fast, low volume and collapsing. • Both legs have sustained multiple fractures, the skin and soft tissues have lacerated from which blood is oozing, but there is no active bleeding. • There is no apparent head injury.
  • 3. • Should any medicine be administered immediately, before even completing a thorough physical examination? • If so, which drug, by what route, and why?
  • 9. Opium • Papaver somniferum and P. album • Rigveda – “soma” • Eber’s papyrus (1500 BC) • Friedrich serturner • Greek god of dreams – “Morpheus”
  • 11. Alkaloids of opium • Opiates vs Opioids
  • 12. OPIOID RECEPTORS • μ, δ, and κ (MOR, DOR, and KOR) • Rhodopsin family of GPCRs (GRAFS classification) • Transducer mechanisms: Gi/Go proteins
  • 14. OPIOID RECEPTORS • μ, δ, and κ (MOR, DOR, and KOR) • Rhodopsin family of GPCRs • Transducer mechanisms: Gi/Go proteins • μ and κ: reduce intracellular cAMP formation and open K+ channels (mainly) • δ: suppresses voltage gated N type Ca2+ channels (mainly) • Neuronal hyperpolarization and reduced availability of intracellular Ca2+ → decreased neurotransmitter release
  • 18. Consequences of opioid receptor activation 1. Internalization 2. Desensitization 3. Tolerance 4. Dependence 5. Addiction
  • 19. Internalization • μ and δ receptors: endocytic, β-arrestin- mediated • κ receptors: do not internalize
  • 20. Desensitization • Acute tolerance or desensitization • Receptor specific • Phosphorylation of the receptors resulting in an uncoupling of the receptor from its G- protein and/or internalization
  • 21. Tolerance • Decrease in the apparent effectiveness of a drug • With continuous or repeated agonist administration (days to weeks) • Following removal of the agonist, disappears over several weeks • Right shift in the dose-effect curve • Cross-tolerance is not consistent or complete
  • 22. Tolerance Mild: • Miosis Moderate: • Constipation • Emesis • Analgesia • Sedation Rapid: • Euphorigenic
  • 23. Dependence “a state of adaptation manifested by receptor/drug class-specific withdrawal syndrome produced by cessation of drug exposure (e.g., by drug abstinence) or administration of an antagonist”
  • 24. Dependence Withdrawal is manifested by • Agitation • Hyperalgesia • Hyperthermia • Hypertension • Diarrhea • Pupillary dilation • Release of virtually all pituitary and adrenomedullary hormones Affective symptoms • Dysphoria • Anxiety • Depression somatomotor and autonomic outflow
  • 25. Addiction “a behavioral pattern characterized by compulsive use of a drug” • Driving force: rewarding effects of opiates • Avoidance and alleviation of withdrawal symptoms
  • 27. • Receptor Disposition • Adaptation of Intracellular Signaling Mechanisms in the Opioid Receptor-Bearing Neurons • System Level Counter-Adaptation
  • 28. Classification Natural opium alkaloids: 1.Morphine, 2.Codeine Semisynthetic opiates: 1.Diacetylmorphine (Heroin), 2.Pholcodeine, 3.Ethylmorphine Synthetic opioids: 1.Pethidine (Meperidine), 2.Fentanyl, 3.Methadone, 4.Dextropropoxyphene, 5.Tramadol.
  • 29. Morphine – Pharmacological actions CNS  Depressant • Analgesia • Sedation • Mood • Respiratory centre • Cough centre • Temperature centre • Vasomotor centre • Thalamus - hypothalamus  Stimulant • CTZ • Edinger Westpal nucleus • Vagal centre • Cortical & hippocampal cells
  • 30. CVS • Vasodilatation • Hypotension • Bradycardia GIT • Constipation  Others • Bronchi: histamine -> bronchoconstriction • Biliary tract: spasm • Urinary bladder: detrussor vs sphincter • Uterus: no significant effect • Hyperglycemia • Pruritus
  • 31. Analgesia • Dose related • Peripheral vs neuritic • Visceral vs somatic • Dull poorly localised vs sharp shooting localised • Pain associated components • Spinal & supraspinal • Peripheral action of opioid
  • 32. Sites of action of Morphine. A: Direct action of opioids on inflamed or damaged peripheral tissues. B: Inhibition also occurs in the spinal cord. C: Possible sites of action in the thalamus.
  • 33. The pain-inhibitory neuron is indirectly activated by opioids, which inhibits an inhibitory (GABAergic) interneuron.
  • 35. Clinical uses  Analgesia • Traumatic • Visceral • Ischemic • Burn • Post operative • Cancer • Renal colic  Acute pulmonary edema & CCF  Cough  Diarrhea  Shivering  Anaesthesia • Surgical anaesthesia • Pre anaesthetic medication
  • 36. Adverse effects • Acute morphine poisoning – Toxicity: 50mg; Lethal: 250mg – Antidote: Naloxone 0.4 to 0.8mg i.v. • Resp. depression & apnea in newborn • CVS: Hypotension & Bradycardia • Allergy & Pruritus • Tolerance & Dependence
  • 37. CASE STUDY A 60-year-old man with a history of moderate chronic obstructive pulmonary disease presents in the emergency department with a broken hip suffered in an automobile accident. He complains of severe pain. • What is the most appropriate immediate treatment for his pain? • Are any special precautions needed?
  • 39. Codeine • Methyl-morphine • Partial agonist at μ opioid receptor with a low ceiling effect • More selective cough suppressant • Degree of analgesia is comparable to aspirin • Demethylation by CYP2D6  morphine • Constipation is a prominent side effect  Rx of diarrhea • Abuse liability is low
  • 40. Heroin • Diacetylmorphine  6-monoacetylmorphine  morphine • Euphorient especially on i.v. injection and highly addicting • Sedative, emetic and hypotensive actions are less prominent • Banned in most countries except U.K
  • 41. LEVORPHANOL • Opioid agonist of the morphinan series • Pharmacological effects parallel those of morphine • Less nausea and vomiting • Metabolized less rapidly than morphine  long acting (t1/2 of 12-16 hr) • D-isomer (dextrorphan) – Devoid of analgesic action – Has inhibitory effects at NMDA receptors
  • 42. Pethidine (Meperidine) • Synthesized as an atropine substitute in 1939 • μ opioid receptor agonist and its actions are blocked by naloxone • Special features: 1. Analgesic potency 2. Onset of action 3. Cough 4. Spasmodic action on smooth muscles 5. Sedation and euphoria 6. Tachycardia 7. Histamine release 8. Local anaesthesia 9. Norpethidine & Serotonin syndrome 10. Preferred opioid analgesic during labour
  • 43. DIPHENOXYLATE • Meperidine congener • Definite constipating effect in humans • Even its salts are virtually insoluble in aqueous solution  less abuse potential • Diphenoxylate hydrochloride is available only in combination with atropine sulfate • Difenoxin, a metabolite of diphenoxylate, – marketed in a fixed dose with atropine
  • 44. LOPERAMIDE • A piperidine derivative • Antidiarrheal effect: o slows GI motility by effects on the circular and longitudinal muscles of the intestine o reduces of GI secretion • Does not penetrate well into the brain due to the exporting activity of P-glycoprotein
  • 45. FENTANYL • Synthetic opioid related to the phenylpiperidines • 80–100 times more potent than morphine • Very important drugs in anesthetic practice because 1. Relatively short time to peak analgesic effect 2. Rapid termination of effect after small bolus doses 3. Cardiovascular safety 4. Capacity to significantly reduce the dosing requirement for the volatile agents
  • 46. METHADONE • Long-acting MOR agonist • Pharmacological properties qualitatively similar to those of morphine • L-methadone -> 8-50 times more potent than D-isomer & has analgesic activity • D-methadone -> possesses antitussive activity -> Lacks respiratory depressant action and addiction liability • Cumulates in tissues on repeated administration — duration of action is progressively lengthened • Abuse potential is rated lower than morphine • Used primarily as substitution therapy for opioid dependence
  • 47. PROPOXYPHENE • Long-acting MOR agonist, strucurally related to methadone • Pharmacological properties qualitatively similar to those of morphine • D-propoxyphene -> 8-50 times more potent than L- isomer & has analgesic activity • L-propoxyphene -> possesses antitussive activity • Marketed only in combination with paracetamol ± other drugs
  • 48. TRAMADOL • Synthetic codeine analog that is a weak μ agonist • Inhibits reuptake of NA and 5-HT Increases 5-HT release Thus activates monoaminergic spinal inhibition of pain • less respiratory depression, sedation, constipation, urinary retention and rise in intrabiliary pressure • ‘serotonin syndrome’
  • 49. TAPENTADOL. • Structurally & mechanistically similar to tramadol • Displays a mild opioid activity • Possesses monoamine reuptake inhibitor activity • Considered similar to tramadol in activity, efficacy and side-effect profile • NUCYNTA
  • 50. • COMPLEX ACTION OPIOIDS AND OPIOID ANTAGONISTS 1. Agonist-antagonists (κ analgesics) Nalorphine, Pentazocine, Butorphanol 2. Partial/weak µ agonist + κ antagonist Buprenorphine 3. Pure antagonists Naloxone, Naltrexone, Nalmefene
  • 51. Nalorphine (Nalbuphine) • N-allyl-normorphine • first opioid antagonist introduced in 1951 • KOR agonist-MOR antagonist • not used clinically because of dysphoric and psychotomimetic effects.
  • 52. Pentazocine • Synthesized as part of a deliberate effort to develop an effective analgesic with little or no abuse potential • Weak μ antagonist and strong κ agonist • Analgesia - spinal (κ1) • Lower ceiling Sedation and respiratory depression • Tachycardia and rise in BP-sympathetic stimulation • Biliary spasm and constipation – less prominent • Low dose – pleasurable; high dose- unpleasurable (σ mediated)
  • 53. Recognised by post-addicts as an opiate Tolerance, psychological and physical dependence ‘Drug seeking’ Withdrawal syndrome has features of both morphine and nalorphine abstinence  Uses: Postoperative and moderately severe pain in burns, trauma, fracture & cancer  Combination of pentazocine with naloxone reduces the potential misuse of tablets
  • 54. Butorphanol • KOR agonist and MOR antagonist • Actions similar to pentazocine • Dysphoric & Psychotomimetic effects are not prominent (weaker σ agonist) • Recognised by post-addicts as an barbiturate Tolerance, physical dependence and withdrawal (mild) • Can neither substitute for, nor antagonize morphine (weak interaction with µ receptors) • postoperative and other short-lasting (e.g. renal colic) painful conditions
  • 56. • It substitutes for morphine at low levels of morphine dependence • Precipitates withdrawal in highly morphine dependent subjects • Long-lasting painful conditions requiring an opioid analgesic (cancer pain) • Premedication, postoperative pain, in myocardial infarction and in the treatment of morphine dependence. • Naloxone (high dose) can prevent buprenorphine effect but does not reverse it - not used during labour
  • 57. Naloxone • It is N-alylnor-oxymorphone • Competitive antagonist on all types of opioid receptors • No – Agonistic action – Autonomic action – Physical/psychological dependence • Antagonizes all actions of morphine • Antagonizes the agonistic actions of nalorphine, pentazocine @higher doses
  • 58. • Naloxone also blocks the actions of endogenous opioid peptides – blocks placebo, acupuncture and stress-induced analgesia • Naloxone partly antagonizes respiratory depression produced by certain nonopioids, e.g. N2O, diazepam
  • 59. • Uses: – drug of choice for morphine poisoning (0.4–0.8 mg i.v. every 2– 3 min: max 10 mg) – reversing neonatal asphyxia due to opioid use during labour – overdose with other opioids and agonistantagonists (except buprenorphine) – diagnosis of opioid dependence
  • 60. Naltrexone • chemically related to naloxone • more potent than naloxone • orally active and having a long duration of action • ‘opioid blockade’ therapy of post addicts • Alcohol craving is also reduced by naltrexone – approved for prevention of relapse of heavy drinking
  • 61. Methyl naltrexone • derivative of naltrexone • does not penetrate the blood-brain barrier • effectively blocks peripheral action of μ opioids • used to reverse constipation in – cancer patients receiving chronic opioid analgesia – those taking methadone maintenance therapy.
  • 62. References :- • Goodman & Gilman’s The Pharmacological Basis of Therapeutics; 12th edition. • Basic & Clinical Pharmacology – Katzung ; 13th edition. • Essentials of Medical Pharmacology - KD Tripathi; 6th edition.